Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.
Martín-Martorell P, Roselló S, Rodríguez-Braun E, Chirivella I, Bosch A, Cervantes A. Martín-Martorell P, et al. Among authors: bosch a. Br J Cancer. 2008 Aug 5;99(3):455-8. doi: 10.1038/sj.bjc.6604530. Br J Cancer. 2008. PMID: 18665167 Free PMC article. Clinical Trial.
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
Hatschek T, Foukakis T, Bjöhle J, Lekberg T, Fredholm H, Elinder E, Bosch A, Pekar G, Lindman H, Schiza A, Einbeigi Z, Adra J, Andersson A, Carlsson L, Dreifaldt AC, Isaksson-Friman E, Agartz S, Azavedo E, Grybäck P, Hellström M, Johansson H, Maes C, Zerdes I, Hartman J, Brandberg Y, Bergh J. Hatschek T, et al. Among authors: bosch a. JAMA Oncol. 2021 Sep 1;7(9):1360-1367. doi: 10.1001/jamaoncol.2021.1932. JAMA Oncol. 2021. PMID: 34165503 Free PMC article. Clinical Trial.
Strategies to design clinical studies to identify predictive biomarkers in cancer research.
Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Perez-Gracia JL, et al. Among authors: bosch a. Cancer Treat Rev. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. Cancer Treat Rev. 2017. PMID: 28088073 Free article. Review.
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. Bosch A, et al. Sci Transl Med. 2015 Apr 15;7(283):283ra51. doi: 10.1126/scitranslmed.aaa4442. Sci Transl Med. 2015. PMID: 25877889 Free PMC article.
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT, Di Tomaso E, Sternberg DW, Massacesi C, Hirawat S, Dirix L, Baselga J. Saura C, et al. Among authors: bosch a. Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27. Clin Cancer Res. 2014. PMID: 24470511 Clinical Trial.
1,138 results